Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Roy Buchanan has given his Buy rating due to a combination of factors highlighting HOOKIPA Pharma's strategic adjustments and partnership potential. Despite the significant workforce reduction and pausing of the eseba-vec cancer vaccine program, Buchanan maintains a positive outlook based on the company's continued focus on promising vaccine programs. The decision to streamline operations and concentrate resources on the KRAS vaccine program and Gilead-partnered HBV and HIV vaccine candidates reflects a strategic shift towards areas with strong development milestones and potential returns.

HOOKIPA's partnership with Gilead is particularly noteworthy, offering substantial financial incentives and revenue opportunities through development and commercial milestones, as well as tiered royalties on net sales. The alignment with Gilead's expertise and resources enhances the potential success of the HBV and HIV programs. Despite the lowered price target, the robust pipeline and strategic collaborations present compelling reasons for the Buy rating.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.